TNF-inhibitors to get stronger US warnings on fungal infections
This article was originally published in Scrip
Executive Summary
The US FDAhas requested that the existing "black box" warnings on the risk of serious infections with marketed tumour necrosis factor inhibitors be strengthened to include the risk of developing opportunistic fungal infections, including histoplasmosis in particular. Some patients with invasive fungal infections have died, the regulator said.